As a result, thirty-two FDA-approved drugs were subjected to virtual screening through docking against MMP-2 and MMP-9 proteins to identify the most promising inhibitors as a proposed computational mechanism to treat KC. This evidence concerns the gene MMP9 and keratoconus.